ESR1 and breast carcinoma: Different hormonal therapy approaches that are currently in use or in clinical development for patients with breast cancer prevent either estrogen synthesis or estrogen binding to nuclear estrogen receptors (ERs), thereby downregulating ER-mediated cell proliferation.